In two phase 3 trials of 1834 adults with noncirrhotic chronic HBV on NA therapy, 24 weeks of bepirovirsen vs placebo gave functional cure at week 72 in 20% vs none (B-Well 1) and 19% vs none (B-Well 2). Grade ≥3 adverse events: 16% vs 3%.
RCTn = 1,834
Hou et al. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection